Renovaro
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 12
- Market Cap
- $106.1M
- Introduction
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
Renovaro Launches Augusta: AI-Powered Platform Aims to Transform Neurological Drug Discovery
Renovaro Inc. has launched Augusta, an AI-powered precision neurology platform that integrates multiomics, phenoclustering, and CRISPR screens to accelerate biomarker and drug discovery for neurological disorders.
Predictive Oncology Sells Skyline Medical Assets to DeRoyal Industries to Focus on AI-Driven Cancer Drug Discovery
Predictive Oncology has completed the sale of its Skyline Medical subsidiary to DeRoyal Industries, allowing the company to focus exclusively on its AI-driven drug discovery platform for cancer research.
Renovaro and BioSymetrics Announce Merger to Accelerate AI-Driven Drug Discovery and Biomarker Development
Renovaro Biosciences and BioSymetrics have entered into a definitive merger agreement, combining TechBio expertise with AI-driven drug discovery capabilities to advance precision medicine in oncology and other diseases.